Lynn A. Tetrault
Lynn A. Tetrault's purchase track record
Lynn A. Tetrault has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/9/2025 | NEO | $57K | -28.0% | +25.2% | +18.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
RYTM: RBC raises price target to $159, maintains Outperform. RBC Capital kept its Outperform rating on Rhythm Pharmaceuticals and lifted its price target to $159. The new target sits well above the stock’s 52‑week high of $122.20 and higher than the consensus analyst target of $138.59. A recent Benzinga piece also highlighted the stock’s five‑year total return, underscoring its past performance. These developments may influence market perception of the company’s growth prospects.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
NeoGenomics Shares Drop 12% on CEO Transition News. NeoGenomics stock fell 12% following the announcement of a CEO succession plan, despite reporting a revenue beat and a strong Q3 outlook. The market reaction highlights how leadership changes can outweigh immediate financial results. Analysts remain mixed, with StoneX raising its price target to $20 while the average target sits at $21.55.
Transaction History
| ALMS | ▲ Buy | Grant | 3,553 | $0 | 6/30/2026 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 4,712 | — | 6/23/2026 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 37,000 | $1.0M | 6/22/2026 | View on chart |
| RYTM | ▼ Sell | Open Market | 37,000 | $3.7M | 6/22/2026 | View on chart |
| NEO | ▼ Sell | Open Market | 5,307 | $59K | 6/15/2026 | View on chart |
| NEO | ▼ Sell | Open Market | 5,307 | $60K | 6/9/2026 | View on chart |
| NEO | ▲ Buy | Option Exercise | 23,077 | $0 | 6/1/2026 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 4,000 | — | 6/18/2025 | View on chart |
| NEO | ▲ Buy | Option Exercise | 12,254 | $0 | 6/1/2025 | View on chart |
| NEO | ▲ Buy | Open Market | 7,000 | $57K | 5/9/2025 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 10,000 | $42K | 9/10/2024 | View on chart |
| RYTM | ▼ Sell | Open Market | 350 | $18K | 9/10/2024 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 7,501 | $142K | 9/10/2024 | View on chart |
| RYTM | ▼ Sell | Open Market | 8,490 | $416K | 9/10/2024 | View on chart |
| RYTM | ▼ Sell | Open Market | 8,661 | $435K | 9/10/2024 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 3,199 | $61K | 9/9/2024 | View on chart |
| RYTM | ▼ Sell | Open Market | 3,199 | $160K | 9/9/2024 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 4,300 | $82K | 8/26/2024 | View on chart |
| RYTM | ▼ Sell | Open Market | 4,300 | $215K | 8/26/2024 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 10,000 | $42K | 8/12/2024 | View on chart |
| RYTM | ▼ Sell | Open Market | 9,593 | $428K | 8/12/2024 | View on chart |
| RYTM | ▼ Sell | Open Market | 407 | $18K | 8/12/2024 | View on chart |
| NEO | ▲ Buy | Option Exercise | 11,336 | $0 | 8/10/2024 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 3,000 | — | 6/21/2024 | View on chart |
| NEO | ▼ Sell | Open Market | 6,112 | $98K | 3/4/2024 | View on chart |
| NEO | ▲ Buy | Option Exercise | 1,507 | $17K | 5/22/2023 | View on chart |
| NEO | ▲ Buy | Grant | 15,556 | $0 | 6/10/2022 | View on chart |
| NEO | ▲ Buy | Option Exercise | 3,334 | $24K | 5/18/2022 | View on chart |
| NEO | ▲ Buy | Grant | 838 | $0 | 10/11/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Alumis reports positive Phase 3 psoriasis data for envudeucitinib
Alumis announced new Phase 3 results showing that its drug envudeucitinib improved scalp psoriasis, itch, and quality of life measures. The company confirmed that the New Drug Application submission is on track for the fourth quarter of 2026. While the clinical data was positive, analysts have expressed a mixed view on the immediate market impact of these results.
Alumis reports positive Phase 3 psoriasis data for envudeucitinib. Alumis announced new Phase 3 results showing that its drug envudeucitinib improved scalp psoriasis, itch, and quality of life measures. The company confirmed that the New Drug Application submission is on track for the fourth quarter of 2026. While the clinical data was positive, analysts have expressed a mixed view on the immediate market impact of these results.